- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Flonase ads failed to disclose risk
The Food and Drug Administration claims that Glaxo Wellcome's Spanish-language television advertisements for Flonase® (fluticasone) nasal spray, which ran in Puerto Rico in 1998 and 1999, failed to disclose risk information.
The Food and Drug Administration claims that Glaxo Wellcome's Spanish-language television advertisements for Flonase® (fluticasone) nasal spray, which ran in Puerto Rico in 1998 and 1999, failed to disclose risk information.
In an August 18 warning letter to the company, the FDA said the ads failed "to provide information relating to the major side effects and contraindications" and failed to make "adequate provision for the dissemination of the approved labeling, or inclusion of the brief summary of information related to the side effects and contraindication in conjunction with the advertisement."
The FDA letter continued: "In fact, the advertisement mentions only the indication for Flonase (relief of nasal allergy symptoms) and provides no risk information at all."
In addition, Glaxo Wellcome failed to submit the ads to the FDA, which requires such submissions at the time of the advertisement's first use.
Glaxo Wellcome has discontinued the ads, but the FDA is requiring that the company "assure FDA that similar advertisements are not being disseminated anywhere in the United States or its territories and possessions." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
